PosterSessionOnline

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 18th World Congress on Gastrointestinal Cancer 2016

June 29 - July 2, 2016 Barcelona

N. Poster

Poster title

Applicant name

Status


2-PD	Response to chemotherapy and prognosis in metastatic colorectal cancer with deficient mismatch repair	ALEXANDRA ALEX	Received

2-P	Suppression of Lipocalin-2 promotes the Epithelial-to-Mesenchymal Transition in human colorectal cancer cells	Se Lim Kim	Received

2-RM	Molecular characterization of gastrointestinal stromal tumours GISTs : The experience ofHassan IIUniversity Hospital-Fez; Morocco	doumbia hamidou dioba	Received

3-P	EXTENDED MUTATIONAL PROFILING FOR METASTATIC COLORECTAL CANCER (CRC): BEYOND RAS MOLECULAR SPECTRUM OF KRAS-NRAS-BRAF AND PI3K IN CANCER COLORECTAL.	SILVINA OTERO	Received

3-PD	Analysis of single-nucleotide polymorphisms (SNPs) in thephase 3 CORRECT trial of regorafenib vs placebo in patientswith metastatic colorectal cancer (mCRC)	Dieter Lambrechts	Received

3-O	Long term follow up in the SCALOP-1 trial: a randomised Phase II trial of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy for locally advanced non-metastatic pancreatic cancer	Somnath Mukherjee	Received

4-O	Effects of nal-IRI (MM-398) 5-Fluorouracil on Quality of Life (QoL) in NAPOLI-1:A Phase 3 Study in Patients With Metastatic Pancreatic DuctalAdenocarcinoma (mPDAC) Previously Treated With Gemcitabine-Based Therapy	Richard Hubner	Received

4-PD	Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study	Federica Marmorino	Received

5-PD	Clinical validation of response and resistance factor candidates to targeted therapy in gastric cancer	Florian Lordick	Received

5-O	Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma - and impact on outcome	Joanne Xiu	Received

6-PD	Final Analysis of Stage 1 Data From a Randomized Phase 2 Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients, Utilizing Ventana Companion Diagnostic Assay	Joseph Takacs	Received

6-P	Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancer	Denis Kutilin	Received

7-O	Biomarker Analyses of Second-Line Ramucirumab in Patients With AdvancedGastric Cancer From RAINBOW, a Global, Randomized, Double-Blind, Phase 3 Study	Eric Van Cutsem	Received

8-RM	SURGICAL EMERGENCIES IN COLORECTAL MALIGNANCIES - PATIENT PROFILE ANALYSIS	Bharathi Mohan Thangasamy	Received

9-O	NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate	ANNALISA ZANUSO	Received

9-PD	Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of ed elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies.	Mariaelena Casagrande	Received

11-RM	Safety and Efficacy of Biweekly Cetuximab Based Chemotherapy for Patients with Metastatic Colorectal Cancer	kamel ahmed	Received

11-P	Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancer	Edita Baltruskeviciene	Received

11-O	Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO	Carlotta Antoniotti	Received

12-P	CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancer	Jia Zhang	Received

13-P	Prognostic Significance of cyclin D1 and p21(WAF1/CIP1) in Gastric Cancer	Vasiliki Michalaki	Received

13-O	A NEW NOMOGRAM FOR ESTIMATING 12-WEEKS SURVIVAL IN PATIENTS (PTS) WITH CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (mCRC)	Filippo Pietrantonio	Received

13-PD	Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)	Takayuki Yoshino	Received

14-P	Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in theConversion from Intestinal Metaplasia to Gastric Cancer?	Ufuk Demirci	Received

14-O	Evaluation of depth of response within a volumetric model in patients withmetastatic colorectal cancer: results of the SIRFLOX study	Farah Dunlop	Received

15-O	Association Between Depth of Response and Survival Outcomes inRASWild-Type Patients With Metastatic Colorectal Cancer Receiving First-LineFOLFOX or FOLFIRI Plus Cetuximab Once Every 2 Weeks In The APEC Study	Gino Randazzo	Received

15-RM	Clinicopathological, epidemiological and outcome of treatment of advanced gastric cancer in Egypt: single institution experience	Ahmed Gaballah	Received

15-P	Detection of genes &1089;opy number variation as predictive markers for metastases in patients with gastric cancer	Denis Kutilin	Received

16-P	Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancer.	Federico Longo	Received

16-PD	Current results of a Phase I study of DKN-01 in combination with paclitaxel (P)in patients (pts) with advanced DKK1 esophageal cancer (EC) orgastro-esophageal junction tumors (GEJ)	Cynthia Sirard	Received

16-RM	Prognostic factors and assessment of postoperative chemoradiotherapy in gastric cancer	Mghirbi Fahmi	Received

16-O	A prognostic marker for colorectal cancer: combining analyses of ploidy and stroma	Susan Fotheringham	Received

17-P	ANALYSIS OF microRNA EXPRESSION IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS	Sandra Jimena Vega Neira	Received

17-PD	A population-based study of gastric adenocarcinoma in Central Norway 2001 - 2011	Erling A Bringeland	Received

17-RM	Systemic chemotherapy in Advanced gastric carcinoma: A comparison of DCF versus CF; versus ECF regimens in clinical setting.A reterospective study	PRAMILA KUMARI	Received

18-O	Clinical application of targeted next generation sequencing for colorectal cancer patients: a multicentric Belgian experience	Nicky DHaene	Received

18-RM	PRECISE SELECTION OF METASTATIC GASTRIC CANCER PATIENTS FOR FIRST LINE, DOCETAXEL BASED CHEMOTHERAPY: A RETROSPECTIVE STUDY.	PRAVEEN KUMAR KHATRI	Received

18-PD	Risk Factors for Metachronous Gastric Carcinoma Development After Endoscopic Resection of Gastric Dysplasia ; Retrospective, Single Center Study	Hee Seok Moon	Received

19-PD	ARQ 087, an Oral Pan- Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced and/or Metastatic Intrahepatic Cholangiocarcinoma (iCCA)	Michele Droz	Received

19-P	Use of serum levels of cytokine TGF &946;1 in detection of Hepatocellular carcinoma in patients with chronic liver disease	Amila Mehmedovic	Received

21-O	Tailored strategy for locally-advanced rectal carcinoma according to the tumor response to induction trichemotherapy: preliminary results of the French phase II multicenter GRECCAR4 trial.	philippe rouanet	Received

21-PD	A Single Centre Experience of the prognostic variables in Hepatocellular carcinoma (HCC) patients treated with Transarterial Chemoembolization	Preetha Aravind	Received

22-P	Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancer	Radmila Jankovic	Received

22-O	A Multi-Institutional Phase 2 Study of Single Agent Nivolumab in Previously Treated Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA).	Amir Mehdizadeh	Received

22-PD	FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study	Caterina Vivaldi	Received

23-PD	Safety Across Subgroups in NAPOLI-1: a Phase 3 Study of nal-IRI (MM-398) 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in MetastaticPancreatic Cancer Previously Treated With Gemcitabine-Based Therapy	Li-Tzong Chen	Received

24-PD	Retrospective Analysis of Quality of life and early tumour Shrinkage During First-line FOlFOX4 Panitumumab in RAS Wild-type metastatic Colorectal Carcinoma	Daniel Booth	Received

24-P	Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control study	Franco Lumachi	Received

25-RM	Chemoradiation for Unresectable Gall Bladder Cancer: Regional cancer centre study.	PRAMILA KUMARI	Received

25-PD	RECOURSE Trial: Impact of Adverse Events on Quality of Life and Duration of Trifluridine and Tipiracil (TAS-102) Treatment	Josep Tabernero	Received

25-O	First-Line FOLFOX-4 Cetuximab in Patients With RASWild-Type Metastatic Colorectal Cancer: The Open-Label,Randomized Phase 3 TAILOR Trial	Gino Randazzo	Received

26-RM	IN GASTROINTESTINAL CANCERS, PATIENTS PERSPECTIVES ON PALLIATIVE CHEMOTHERAPY : A PROSPECTIVE STUDY	PRAVEEN KUMAR KHATRI	Received

26-O	Combination of Encorafenib and Cetuximab With or Without Alpelisib in Patients With Advanced BRAF-Mutant (BRAFm)Colorectal Cancer: Phase 2 Results	Josep Tabernero	Received

26-P	Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancer	Gulrukh Botiralieva	Received

26-PD	Survival Outcomes in Patients with RAS Wild-type metastatic Colorectal Cancer Classified by Khne Prognostic Category and BRAF mutation Status: Retrospective Analysis of the PRIME Study	Dan Booth	Received

27-P	Cancer stem cells marker CD44 and NOTCH activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapy	Francesca Negri	Received

28-PD	Retrospective Analysis of Impact of Khne Prognostic Category and BRAF mutation Status on Survival in Patients with RAS Wild-type metastatic Colorectal Cancer treated With Second-line FOlFIRI With/Without Panitumumab	Daniel Booth	Received

28-RM	Gemcitabine in Combination With capcitabine Compared With Gemcitabine combined with Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer	PRAVEEN KUMAR KHATRI	Received

28-P	Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)	john souglakos	Received

29-RM	Outcome of continuous infusion of low dose gemcitabine in locally advanced and metastatic pancreatic carcinoma	Salah Mabrouk Khallaf	Received

30-RM	Phase III study of Capecitabine and Oxaliplatin versus 5-fluorouracil in Neoadjuvant Chemoradiation for Locally Advanced Rectal Carcinoma	Marwa Khalaf	Received

30-P	Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancer	Vincenzo Ricci	Received

31-PD	An exploratory Study-level meta-Analysis Assessing the Impact of early tumour Shrinkage on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Cancer Receiving First-line treatment in three Randomised Panitumumab trials	Daniel Booth	Received

31-RM	Preoperative short-course chemoradiation with consolidation with consolidation chemotherapy and delayed surgery in locally advanced rectal cancer( T3-T4 or N )	Sarvazad Sotoudhe	Received

32-RM	Neoadjuvant Chemoradiotherapy and Chemotherapy in Patients with Locally Advanced Rectal Cancer	Marwa Khalaf	Received

32-PD	Evolution of efficacy and safety of cetuximab with the determination of RAS status in Metastatic Colorectal Cancer (mCRC) elderly patients	Fanny MARHUENDA	Received

32-P	A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC).	Magdalena Krakowska	Received

33-RM	Rectal Cancer in Patients Younger than 40 at AUBMC: Tumor Characteristics and Com- parative Survival and Disease Free Survival	Ali Shamseddine	Received

34-PD	Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the U.S.	Thomas Abrams	Received

35-P	Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with STAGE IA-IB gastric cancer. A case-control study	Franco Lumachi	Received

35-PD	Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial	Kazuhiro Nishikawa	Received

36-P	Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric Cancer	Soo A Choi	Received

36-PD	Maintenance chemotherapy or Observation alone following Gemcitabine-Platinum combination palliative chemotherapy in locally advanced and/or metastatic gallbladder cancer - a single tertiary care centre experience in South Asia	Rakesh pinninti	Received

37-RM	Neo-adjuvant FOLFIRINOX in borderline resectable/locally advanced pancreatic adenocarcinoma	Ali Shamseddine	Received

37-P	The Role of Carcino-embryonic Antigen Testing among Western Patients with Resected Gastric Cancer	Erin Greenleaf	Received

38-RM	Modified GTX second-line therapy in pancreatic adenocarcinoma	Ali Shamseddine	Received

39-PD	Role of adjuvant radiotherapy following neo-adjuvant chemotherapy (NACT) and surgery in oesophageal cancer a multi-centre retrospective cohort study	Somnath Mukherjee	Received

39-P	5-FU DEGRADATION RATE IN PATIENTS WITH RECURRENT GASTROINTESTINAL CANCER TREATED WITH METRONOMIC CAPECITABINE	Michela Roberto	Received

40-PD	Risk assessment for gastrointestinal cancers in patients with family history of gastrointestinal cancer: Multi-center interim analysis study in the Republic of Korea	Joo Won Chung	Received

41-P	IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma.	Marlid Cruz	Received

41-RM	Risk of selected gastrointestinal toxicities in cancer patients treated with Pazopanib; a systematic review and meta-analysis	lamiaa abdallah	Received

42-P	The genetic profile of pancreatic circulating tumor cells	Maria Papadimitriou	Received

43-P	Significance of bcl-2 in rectal cancer recurrences	Gulrukh Botiralieva	Received

43-RM	Eruptive seborrheic keratosis (ESK) and its association with gastrointestinal cancer (GIC). A case-control study and meta-analysis	Jesus Insuasty	Received

45-RM	PRE-OPERATIVE DIAGNOSIS IN PANCREATIC TUMORS -REALITY OR MYTH?	Dr. Bharathi Mohan Thangasamy	Received

45-P	Resistant form of helicobacter pylori in development of stomach MALT lymphoma	Makhsud Mallaev	Received

47-P	Sorafenib after locoregional treatments for advanced or recurrent hepatocellular carcinoma	Catarina Ribeiro	Received

48-P	Prognostic Impact of CA19-9 Level at Diagnosis in Pancreatic Adenocarcinoma: A U.S. Population Study	Katelin Mirkin	Received

49-P	A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in Russia	Mikhail Fedyanin	Received

49-RM	Colorectal cancer in Medan Indonesia. A single centre report	Sry Widjaja	Received

50-RM	Lifestyle habits and dietary patterns in gastric cancer patients in Toungoo; Myanmar	Khin Khin Nwe	Received

50-P	THE PHARMACOLOGICAL COSTS OF FIRST-LINE THERAPIES IN UNSELECTED ADVANCED COLORECTAL CANCER PATIENTS: A REVIEW OF PUBLISHED PHASE III TRIALS	Jacopo Giuliani	Received

51-RM	Evidence-based assessment of the burden of infection related solid tumors	Ahmed Alnagar	Received

51-P	Clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI Aflibercept (FA). Preliminary results.	Carles Pericay Pijaume	Received

52-RM	PANCREATIC CANCER OUR EXPERIENCE (EPIDEMIOLOGY).	Recioui Abdallah	Received

53-RM	A Clinico epidemiological study of non metastatic gastrointestinal stromal tumor A prospective observational multi institutional study from Southern India	KRISHNAKUMAR RATHNAM	Received

55-P	Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk	Mototsugu Shimokawa	Received

56-P	Outcome of Maintenance Therapy in Patients Who Achieved NED After Liver Resection for mCRC	marwan al-hajeili	Received

57-P	Body Composition, beyond Body Mass Index and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer	Camille Van Bogaert	Received

59-RM	The effect of adjuvant chemotherapy folowing extended total gastrectomy for Siewerts type II adenocarcinoma of the esophagogastric junction	Ramiz Bayramov	Received

61-P	Use of aflibercept in colorectal cancer patients - real world experiences in the North West	Nicola Flaum	Received

63-RM	Neoadjuvant Chemotherapy for Unresectable Gall Bladder Carcinoma : Our experience	Sandeep Bhoriwal	Received

63-P	Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy inpatients with metastatic colorectal cancer (mCRC) results from the SIRFLOX study	Farah Dunlop	Received

64-P	Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancer	Marija Ristic	Received

66-RM	Histological diagnosis of gastric submucosal tumors after endoscopic submucosal dissection	Olena Kuryk	Received

66-P	New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in colon cancer patients during adjuvant treatment with 5-fluorouracil/oxaliplatin	Joanna Szpejewska	Received

68-P	Cetuximab in addition to oxaliplatin, fluouracil and radiotherapy for patients with esophageal cancer treated without surgery	Gabriella Alexandersson von Dbeln	Received

69-P	Neoadjuvant chemotherapy for esophageal cancer: Comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin)	Hideaki Shimoji	Received

71-P	Clinical relevance of histologic subtypes in esophageal carcinoma treatedwith neoadjuvant chemo-radiotherapy.	Mariaiconcologia.net Saigí	Received

72-P	Pattern of recurrence and efficacy of salvage therapy after relapse in locally advanced esophageal carcinoma treated with preoperative chemoradiotherapy plus surgery	MARC OLIVA	Received

73-P	Non surgical management of Oesophageal cancer- a retrospective audit with 10 year follow up	Ravi Kodavatiganti	Received

74-P	DISTANT OUTCOME OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE AND METASTATIC OESOPHAGEAL CANCER AFTER MULTIMODALITY TREATMENT	Luiza Serbanescu	Received

76-P	Integrating CROSS style chemotherapy regime into higher doses of radiation for the radical treatment of localized oesophageal carcinoma in patients with borderline fitness.	Pei Shuen Lim	Received

81-P	Phase II study of adjuvant chemotherapy with S-1 plus Oxaliplatin for gastric cancer	Lin Yang	Received

82-P	Three years of metastatic gastric cancer follow up in our hospital	Marta Ferrer	Received

86-P	Clinical outcome after Endoscopic Submucosal Dissection for Early Gastric Cancer of Absolute and Expanded Indication ; Retrospective Single Center Study	HYUK SOO EUN	Received

87-P	A phase II study of a combination treatment of alternate-day S-1 and lentinan as first-line chemotherapy for unresectable or recurrent gastric cancer	Shigefumi Yoshino	Received

92-P	PERIOPERATIVE CHEMOTHERAPY IN GASTRIC ADENOCARCINOMA- PROGNOSTIC FACTORS IDENTIFICATION	Cristiana Marques	Received

93-P	IS THERE STILL A ROLE FOR ADJUVANT RADIOTHERAPY IN THE CASE OF PATIENTS WITH PRIMARY RESECTABLE GASTRIC CANCER?	Luiza Serbanescu	Received

94-P	Early and long-term outcomes of gastric cancer patients treated with perioperative chemotherapy and radical surgery in a single cancer center	Paulyne Viapiana	Received

97-P	Hepatic Artery Embolization (HAE) In Hepatocellular and Gastroenteropancreatic Neuroendocrine Tumors at Instituto Oncologico Nacional. Panama.	Omar Castillo-Fernandez	Received

98-P	Prognostic Significance of Comorbidities in elderly patients with Hepatocellular carcinoma (HCC) treated with Transarterial Chemoembolization: A Single Centre Experience	Preetha Aravind	Received

102-P	Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma	Catarina Ribeiro	Received

103-P	Prognostic factors for survival in patients with advances intrahepatic cholangiocarcinoma treated with gemcitabine plus cisplatin as first line treatment	Utako Ishimoto	Received

104-P	A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer	Hee Man Kim	Received

105-P	Surveillance CT in patients with complete remission following curative chemoradiotherapy for Anal Cancer (Single Centre experience)	Christos Mikropoulos	Received

106-P	M.D., Ph.D.	Seung Taik Kim	Received

107-P	EPIDEMIOLOGY OF LYMPHOMAS INVOLVING THE GASTRO INTESTINAL TRACT : A MULTICENTRE RETROSPECTIVE STUDY FROM SOUTHERN INDIA	KRISHNAKUMAR RATHNAM	Received

108-P	Role of adjuvant treatment in periampullary carcinoma	Saphalta Baghmar	Received

109-P	MALT-Lymphoma - always a good prognosis?	Garcia Ana Rita	Received

111-P	Correlation of Mitotic Index and Ki-67 and Their Impacts on Survival of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at Ramathibodi Hospital	THITIYA DEJTHEVAPORN	Received

112-P	Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.	PRAMILA KUMARI	Received

115-P	Weight Loss during 1st-line chemotherapy for upper gastrointestinal malignancies (UGI) may impact survival and access to further treatment lines	Georgios Oikonomopoulos	Received

116-P	PALLIATVE THERAPY IN UNRESECTABLE ADVANCED GALL BLADDER CANCERS, A RETROSPECTIVE STUDY	PRAVEEN KUMAR KHATRI	Received

117-P	Phase II study of combination chemotherapy of gemcitabine/S-1 with nafamostat mesilate for advanced unresectable pancreatic cancer: First report.	Tadashi Uwagawa	Received

119-P	Chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study	Yuta Maruki	Received

120-P	Gemcitabine nab-paclitaxel as first-line chemotherapy for Japanese patients with advanced pancreatic cancer in real-world clinical practice: a retrospective study	Toshifumi Yamaguchi	Received

121-P	Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer	Matthew Chau	Received

122-P	Phase I study of S-1, irinotecan plus oxaliplatin combination therapy (S-IROX) for unresectable pancreatic ductal adenocarcinoma	Mitsuhito Sasaki	Received

123-P	Clinical Experience of the Efficacy and Safety of two FOLFIRINOX Variants for Inoperable Pancreatic Cancer	Malcolm Buhagiar	Received

124-P	FOLFIRINOX in borderline resectable pancreatic carcinoma	Esther Una Cidon	Received

125-P	Gemcitabine-induced pseudocellulitis in patients with pancreatic adenocarcinoma or cholangiocarcinoma	Esther Una Cidon	Received

126-P	PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma	Ori Farber	Received

128-P	Outcomes with Watch-and-Wait after Pelvic Radiotherapy for Rectal Cancer in East Kent	Rakesh Raman	Received

129-P	Survival rates of patients with rectal cancer in the Department for General and Abdominal surgery University Clinical Center Maribor, who underwent surgery between 2004 and 2014	Nuhi Arslani	Received

130-P	Impact of age on efficacy of neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC)	German Calderillo	Received

132-P	The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients	Consuelo Diaz	Received

133-P	ASSESSMENT OF SEXUAL DYSFUNCTION IN RECTAL CANCER SURVIVORS	Joana Rodrigues	Received

134-P	Parthenolide suppresses hypoxia-induced angiogenesis and epithelial-mesenchymal transition by regulating hypoxia inducible factor 1 alpha signaling in colorectal cancer	Se Lim Kim	Received

135-P	The role of Angiotensin II subtype IA receptor on liver metastasis formation	YUKI SHIMIZU	Received

137-P	Macrophage coculture enhanced invasion of gastric cancer cells via FOXQ1 pathway	Jia Zhang	Received

138-P	Is HER2 positivity gastric cancer good prognostic sign?- our experiences	Milka Vjetica	Received

139-P	Monitoring of plasma concentrations of erlotinib (ERL) after long time administration of 100mg in advanced pancreatic cancer patients	Azra Sahmanovic	Received

140-P	Significant intraoperative blood loss predicts poorprognosis after hepatectomy following neoadjuvantchemotherapy for liver-only colorectal metastases	Mafalda Costa Neves	Received

141-P	Treatment approaches for resectable colorectal cancer metastases in the liver exhibiting poor prognosis	Sergey Khays	Received

142-P	Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer.	Encarnación González-Flores	Received

143-P	The evaluation of liver resection for colorectal cancer liver metastasis	Masaichi Ogawa	Received

144-P	ANTI-EGFR MONOCLONAL ANTIBODIES AND SURGERY OF METASTASES IN THE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC)	Anna Storozhakova	Received

145-P	Metastases resection following FOLFIRI-aflibercept in refractory patients to first-line chemotherapy: safety and efficacy analysis	Andres Muñoz Martín	Received

146-P	Colorectal cancer patients with lung-only metastases have a favorable prognosis irrespective of treatment	Moran Gadot	Received

147-P	Final analysis : Phase II trial of Irinotecan/S-1/Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC : HGCSG0902. -Comparison of administration interval in Cetuximab treatment.	Satoshi Yuki	Received

148-P	RECURRENCE FREE SURVIVAL AS A PUTATIVE SURROGATE FOR OVERALL SURVIVAL IN PHASE III TRIALS OF CURATIVE-INTENT TREATMENT OF COLORECTAL LIVER METASTASES: SYSTEMATIC REVIEW	Raphael Araujo	Received

149-P	Impact of Sequence of Biologic therapies on Overall Survival in Patients with RAS Wild-type metastatic Colorectal Carcinoma: An exploratory, Retrospective Pooled Analysis	Daniel Booth	Received

150-P	Locoregional therapy in liver dominant metastatic colorectal cancer having failed standard drug therapy: Outcome and prognostic parameters in 133 consecutive patients	Stefan Pluntke	Received

151-P	The expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in patients with colorectal adenocarcinoma and lymph node metastases	Franco Lumachi	Received

152-P	Observational Cohort Study of 1st line Bevacizumab Combined with Chemotherapy in Metastatic Colorectal Cancer (HGCSG0802): Sub-group Analysis by the Glasgow Prognostic Score (GPS).	Takuto Miyagishima	Received

154-P	Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer (mCRC) patients	Marcela Crosara Teixeira	Received

155-P	Unresectable colorectal cancer liver metastases: retrospective review and survival analysis	lourdes calera Urquizu	Received

156-P	Pathologic response of liver metastases from colorectal cancer after chemotherapy and aflibercept. Initial report of 23 cases from 9 patients	Frédéric Bibeau	Received

157-P	A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)	Shigeyoshi Iwamoto	Received

158-P	RADIOEMBOLIZATION (SIRT) AS A CONSOLIDATION TREATMENT IN COLORECTAL LIVER METASTASES AFTER FIRST LINE CHEMOTHERAPY: EFFICACY AND SAFETY.	SALVATORE CAPONNETTO	Received

159-P	Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: a multicenter retrospective comparison study	hironaga satake	Received

160-P	Impact of KRAS mutation on patterns of metastasis in a series of colorectal cancer patients	Marta Domenech Viñolas	Received

161-P	5-FU based chemotherapy with Bevacizumab in synchronous metastatic colorectal cancer patients with bleeding primary tumor	Birgit Gruenberger	Received

162-P	IS RESECTION THE ONLY CHOICE FOR THE TREATMENT OFBILOBAR COLORECTAL CANCER METASTASES?	Antonio Chiappa	Received

164-P	Synchronous disease does not predict long-term outcomes in patients with resected colorectal cancer liver metastases	Marcio Marques	Received

165-P	Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matters?	Nieves Martinez Lago	Received

166-P	Re-hepatectomy is a predictor of long-term survival in patients that recur after liver resection of colorectal liver metastases	Marcio Marques	Received

167-P	Cetuximab rechallenge in metastatic colorectal cancer patients	Amanda Nogueira	Received

168-P	Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer	Hiroshi Nakatsumi	Received

169-P	Outcomes of metastatic gastroesophageal cancer patients treated with third line therapy: A 5-year retrospective analysis at a single centre	Chau Ng	Received

170-P	A Biweekly S-1 and nab-paclitaxel as first-line chemotherapy in patients with unresectable or recurrent gastric cancer	Lin Yang	Received

171-P	The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer.	Akitaka Makiyama	Received

172-P	Intraperitoneal aerosol chemotherapy (PIPAC) is a new approach in the treatment of patients with peritoneal сarcinomatosis	Anna Utkina	Received

173-P	OUTCOMES OF PALLIATIVE GASTRECTOMY IN 549 ASYMPTOMATIC PATIENTS WITH ADVANCED GASTRIC CANCER	Valentina Fanotto	Received

174-P	Ramucirumab and Paclitaxel in Platinum-refractory Advanced or Metastastic Gastric or Gastroesophageal Junction Adenocarcinoma a Single Center Experience	Ursula Vogl	Received

175-P	EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA	Paulo Salamanca	Received

177-P	Stereotactic Radiotherapy (SRT) versus Whole Brain Radiotherapy (WBRT) in the management of 1-3 brain metastases (BM) originating from a gastrointestinal (GI) tract malignancy.	Pei Shuen Lim	Received

178-P	Capecitabine and temozolomide (CAPTEM) in patients with advancedneuroendocrine tumors: the experience of a portuguese cancer center.	Andreia Chaves	Received

182-P	An experience of FOLFIRINOX chemotherapy in advanced Pancreatic Cancer	Yazan Haddadin	Received

183-P	Abrogation of alcohol dehydrogenase-1B (ADH1B) expression by CD90 stromal cells supports tumor-promoting inflammation in colorectal cancer	Romain Villéger	Received

185-P	Overexpression of SIRT 6 induces apoptosis in hepatocellular carcinoma mediated by Wnt/&946;-catenin signaling pathway	SOO MI KIM	Received

189-P	Evaluation of short-term quality of life changes after surgery in elderly patients with colorectal cancer using the Medical Outcomes Study short form (MOS-SF-36) questionnaire	Franco Lumachi	Received

192-P	Ocular toxicities with oxaliplatin continue overlooked	Esther Una Cidon	Received

195-P	The impact on comorbidities in deciding the dose for the first cycle of chemotherapy	Esther Una Cidon	Received

196-P	Gastrointestinal stromal tumors: Fifteen years of experience in a Portuguese Hospital Centre	Sílvia Lopes	Received

197-P	INTRAOPERATIVE SENTINEL LYMPH NODE POSITIVITY BY METHYLENE BLUE DYE AND ITS ASSOCIATION WITH OTHER DISSECTED LYMPH NODE BY HISTOPATHOLOGICAL EXAMINATION IN COLORECTAL CANCER	Dr.Bharathi Mohan Thangasamy	Received

199-P	Dosing first cycle of chemotherapy in colorectal cancer: is BSA used for everybody?	Esther Una Cidon	Received

200-P	A Study on Response for Irreversible Electroporation of Colon Cancer Cell using Multiphoton Microscopy	Jung Min Lee	Received

201-P	A Comparative Study for Effectiveness of Irreversible Electroporation Ablation according to Therapeutic Method: Colon Cancer Animal Model	Jung Min Lee	Received

203-P	Assessing intratumor heterogeneity and evolutionary distance in exome sequencing of colon cancer	Ulrich Popper	Received

206-P	Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer	Toru Kurata	Received

207-P	Protective Effect of Ursodeoxycholic acid in the Chemotherapy Induced Mucositis : an In Vitro Animal Experiment	Jung Min Lee	Received

208-P	Pre-therapy functional and body status of patients with advanced gastrointestinal cancer compared to breast cancer patients and healthy women	Katrin Stuecher	Received

209-P	Maintenance BEZ235 treatment following BEZ235 and radiation treatment prolongs the therapeutic effect in colorectal cancer	Ming-Feng Wei	Received

212-P	An investigation of the association between sarcopenia and post-operative morbidity and mortality in patients with gastric cancer	Stephen OBrien	Received

214-P	Salvage Chemoradiotherapy for Locally Recurrent Bile Duct Cancer	Jeong Il Yu	Received

216-P	Treatment of squamous cell anal cancer with IMRT and simultaneous hypofractionated boost combined with concurrent chemotherapy	Laura Diaz	Received

217-P	Chemoradiotherapy with IG - VMAT & IG - IMRT to treat Squamous Anal Cancer	Peter Correa	Received

222-P	Comparison of Investigator-Delineated Gross Tumor Volumes and Quality Assurance in Pancreatic Cancer: Analysis of the On-trial cases for the SCALOP Trial	SOMNATH MUKHERJEE	Received

224-P	Locally advanced rectal cancer:A single institution experience	Nuria Dueñas	Received

226-P	Rectal Bioelectrical impedance (REBI) as a possible screening tool for colorectal cancer (CRC)	Edelberto Mulett	Received

227-P	Comparative characteristics of somatic mutations in the KRAS gene in patients with colorectal cancer the South of Russia	Denis Kutilin	Received

228-P	Inhibitory effects of Lactobacillus helveticus SBT2171 on the proliferation of colorectal tumor cells and the action mechanism	Kazunobu Baba	Received

229-P	An Evaluation Based on a Systematic Review of Epidemiologic Evidence of Colorectal Cancer Risk among the Alcohol Consuming Indian Population	DR ANCHAL NAVNEET MISHRA	Received

230-P	Muir-Torre Syndrome diagnostic and screening. A single center experience	Elizabeth Inga	Received

231-P	PHYSICAL ACTIVITY AND BARRETTS OESOPHAGUS	Sylwia Gugala	Received

232-P	The value of echinococcosis in development of liver cancer.	Aziza Almanova	Received

234-P	Incidence of Sarcopenia and its relationship with Body Mass Index in colorectal cancer patients.	Vasileios Alivizatos	Received

235-P	HOW OFTEN DOES THE PATIENT REPEAT SCREENING COLONOSCOPY?; A STUDY FOR PERSONALIZED RECOMMENDATION OF SCREENING COLONOSCOPY INTERVAL	Jung Min Lee	Received

236-P	Screening Practices of Australians Following Partial Roll-out of the National Bowel Cancer Screening Program, 2009-2012	Louisa Flander	Received

237-P	Comparison of adenoma detection by polypectomy during both insertion and withdrawal versus only withdrawal of colonoscopy: a randomized, controlled multicenter trial	Jeong-Seon Ji	Received

240-P	Vitamin D levels in oesophageal and gastric cancer patients and their outcome	Subodha Thanthulage	Received

242-P	MORTALITY TREND FOR HEPATOCELLULAR CARCINOMA IN ALBANIA: A HEPATITIS B VIRUS ENDEMIC AREA	Fatjona Kraja	Received

243-P	Undiagnosed chronic liver disease (CLD) in patients presenting with Hepatocellular Carcinoma (HCC)	Pavlina Spiliopoulou	Received

244-P	Cholangiocarcinoma: A restrospective analysis of our experience in diagnosis, prognostic factors, staging and treatment.	Elizabeth Inga	Received

246-P	Survival Patterns of Stage IV Pancreatic Cancer: a Population-Based Study	Mohammed Mousa	Received

247-P	Young patients under 40 age with colorectal cancer have poor survival	PRAMILA KUMARI	Received

248-P	Helicobacter pylori translocation to the regional lymph nodes in patients with gastric carcinoma	Paulyne Viapiana	Received

249-P	Short-term results of surgery in elderly (65 years) versus younger patients with Stage I-II colonic adenocarcinoma. A case-control study	Franco Lumachi	Received

253-P	Multimodal analgesia combined with epidural anesthesia and intravenous administration of acetaminophen in perioperative management of esophagectomy using modified ERAS protocol	Takashi Ogata	Received

254-P	Esophagectomy with cervical anastomosis has a greater need for intervention for dysphagia than intrathoracic anastomosis	Yaron Perry	Received

257-P	Surgical treatment of patients withneuroendocrine neoplasms of the stomach	Ivan Peregorodiev	Received

258-P	5-Year Survival of Gastric Cancer Patients after Radical Surgery was Significantly Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System and Adjuvant Treatment	Oleg Kshivets	Received

259-P	Laparoscopic gastrectomy: our technique, complications and long-term oncological results.	Dmytro Golub	Received

260-P	Outcomes of laparoscopic and open gastrectomy for gastric cancer: a comparative analysis	Bárbara Castro	Received

261-P	SURVIVAL AND DISEASE-FREE SURVIVAL IN A CONSECUTIVE MONOCENTRIC SERIES OF MORE THAN 1000 D-2 GASTRIC RESECTION FOR CANCER	Antonio Chiappa	Received

262-P	Multivisceral resections for gastric cancer - Should all patients with locally-disease receive them?	Paulyne Viapiana	Received

263-P	Laparoscopic versus open distal gastrectomy for gastric cancer: a single-center case-control study	Bárbara Castro	Received

264-P	Is laparoscopic approach an option in resection of advanced gastric cancer?	Bárbara Castro	Received

266-P	Highlight of benefits in cirrhotic patient of laparoscopic resection for malignant tumor, retrospective study with propensity score analysis	Fabien Le Roux	Received

268-P	SURGICAL OUTCOMES AND STRICT FOLLOW-UP OF RETROPERITONEAL SOFT-TISSUE SARCOMA	Antonio Chiappa	Received

271-P	Feasibility of neoadjuvant chemotherapy with modified FOLFOX6 (combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent oxaliplatin) with bevacizumab in patients with advanced lower rectal cancer.	Chihiro Kosugi	Received

273-P	Hepatectomy followed by adjuvant chemotherapy with capecitabine plus oxaliplatin for three months for liver metastases from colorectal cancer: a multicenter phase 2 study	hironaga satake	Received

277-P	A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)	Michel Ducreux	Received

278-P	Phase Ib/II study of nivolumab plus CAPIRI: Initial results of metastatic colon cancer and pancreatic adenocarcinoma patients.	Vivek Khemka	Received

281-P	JAVELIN Gastric 100: phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locallyadvanced or metastatic gastric or gastro-oesophageal junction cancer	Kathryn Boothroyd	Received

282-P	JAVELIN Gastric 300: phase 3 trial of avelumab (anti-PD-L1 antibody) best supportive care (BSC) vs BSC chemotherapy as third-line treatment for advanced gastric or gastro-oesophageal junction cancer	Kathryn Boothroyd	Received

285-P	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Following First-Line Sorafenib (REACH-2)	Emily Cullinan	Received

287-P	Nanoliposomal Irinotecan (nal-IRI)-Containing Regimens Versus nab-PaclitaxelPlus Gemcitabine as First-Line Therapy in Patients With Metastatic PancreaticAdenocarcinoma: A Randomized, Open-Label Phase 2 Study	Andrew Dean	Received

288-P	Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) vs placebo, both with Nab-Paclitaxel and in pts With Previously Untreated, Hyaluronan (HA)-High, Stage IV Pancreatic Ductal Adenocarcinoma	Joseph Takacs	Received

289-P	Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study	Annie LIM	Received

ESMO 18th World Congress on Gastrointestinal Cancer 2016

June 29 - July 2, 2016 Barcelona

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 29/06/2016 TO 02/07/2025

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.18wgic.2016



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access